



Investor Pitch Deck

An integrated One-Health genomics platform - Rwanda & East Africa



PROJECT iGiTREE EXECUTIVE SUMMARY

An opportunity to invest in a Family Tree, biotechnology Ecosystem centered on DNA-based family reunification can be positioned as both a humanitarian initiative and a scalable genomics enterprise.

The idea is to build a trusted genomic infrastructure that begins with family identification but expands into livestock precision biotechnology research.

Introduction.

iGiTREE is a Rwanda-based biotechnology and cultural innovation company founded in 2021, operating at the intersection of heritage preservation, genomics and data-driven technology. Its name draws from *iGisekuruza*, the Kinyarwanda concept of lineage, and the symbolism of a family tree, reflecting the company's original mission to digitize and safeguard ancestry, identity and generational continuity. iGiTREE has followed a phased development journey. It began with digital family trees as a cultural and educational resource, enabling individuals and communities to document lineage, preserve family histories and strengthen identity through a structured digital platform. This foundation has provided a pathway toward more advanced genomic and data-driven applications.

The Need.

The company's original family-tree platform provides a foundation for DNA-based family reunification, particularly for survivors of the 1994 Genocide against the Tutsi, refugees and other forcibly displaced communities. By combining genetic matching with documented lineage information, iGiTREE aims to reconnect individuals with biological relatives and broader family structures. The model has already supported family-reunification cases involving individuals separated for decades.

The Foundation.

Building on this foundation, iGiTREE is expanding into human genomic research and surveillance, including population genomics, pathogen monitoring and antimicrobial-resistance research, through partnerships with national institutions and research collaborators. These capabilities are intended to support genomic reference development, public-health intelligence, diagnostics and future pharmaceutical research. The platform has also expanded into animal genomics and environmental surveillance. In livestock, iGiTREE applies genomic profiling to support productivity, breeding, disease resilience and traceability, while contributing to the conservation of indigenous breeds such as Inyambo.

By converting genetic insights into practical tools, such as breeding recommendations, health-risk screening, and lineage verification, iGiTREE empowers farmers and national programs to achieve measurable improvements in productivity, herd quality, and long-term sustainability.

Investment Required.

iGiTREE is seeking to raise a proposed corporate bond of FRW 2.5 billion, with a seven-year repayment period. The financing is intended to support technology development, genomic programmes, commercial expansion and operational scale-up. The financial projections that follow present the company's projected growth, profitability and deleveraging pathway under the proposed investment plan.

**Commercially scalable, financially investable, and strategically aligned
with Rwanda's national development ambitions.**

Rationale

Commercially
scalable data
platform
&
strong projected
financial outlook

Alignment
With the nation
blueprints

Descriptions

- iGiTREE aims to integrate human, animal, environmental and educational genomics into a commercially scalable, data-compounding platform, supported by a unified research and innovation centre.
- Strong projected financial outlook. With appropriate financing, net margin is projected to increase from 12% to 52% by 2033, while ROA remains in the 20-25% range. Leverage is projected to decline from 7.6x to 1.28x as retained earnings increasingly support growth.

Alignment with Rwanda Vision 2050.

- Human Development
Supporting Rwanda's ambition for high-quality, accessible and affordable healthcare, alongside the development of a vibrant pharmaceutical and biomedical research ecosystem.
- Animal Development & Research
Using genomics to improve livestock productivity, genetic resilience and conservation.
- Research & Innovation.
iGiTREE's DNA-based family reunification initiative contributes to Rwanda's broader ambitions in scientific research, biotechnology, human development and innovation under Vision 2050.



VISION & MISSION

A One Health genomics platform built for Africa's genomic decade.**Mission & Vision.****Mission**

Democratize access to genomics across human, animal & environmental health in Africa.

**Vision**

Build an African pharmaceutical company powered by genomic intelligence, with datasets that can become a valuable foundation for pharmaceutical research and development..

MARKET · MODEL · EDGE.**Market**

USD 4.6B African genomics opportunity, growing at ~25% CAGR to 2032.

**Model**

Recurring sample-based revenue today, evolving into licensable genomic IP and data products..

**Model**

An integrated genomics platform spanning human, animal and environmental applications, with potential for data-driven research, healthcare and biotechnology..



Business Model integration



Digital Family Tree

iGiTREE's human genomics offering combines DNA analysis with AI-assisted matching, integrated into a secure digital family-tree platform and culturally grounded storytelling (Ibisekuruza), making it relevant to genocide against the Tutsi survivors, refugees and diaspora communities seeking reconnection.

Key requirements in this space include trust, robust data governance, and strong local partnerships with governmental and humanitarian institutions. These are areas where iGiTREE is developing experience and partnerships, supporting credibility and adoption of its reunification services.



Animal Genomics

In animal genomics, iGiTREE offers a differentiated per-animal genomics package incorporating DNA profiling, productivity and disease-risk assessment, mating recommendations, lineage traceability and market-value guidance. The model is designed to generate measurable value for farmers while supporting the conservation of culturally significant breeds such as the Inyambo.

Key implementation requirements include field-level sample logistics, validated genetic-trait panels and credible reporting trusted by farmers, cooperatives and lenders. iGiTREE is developing structured workflows and certification templates to address these requirements.




Genome Surveillance & Antimicrobial Resistance R&D - Public Health

In public-health genomics, iGiTREE is developing a wastewater-based pathogen and antimicrobial-resistance (AMR) surveillance model combining environmental sampling, targeted community monitoring and early-warning dashboards for ministries, utilities and humanitarian agencies.


The model is designed to differentiate iGiTREE by connecting surveillance data with actionable policy dashboards and a pathway toward pharmaceutical and diagnostic R&D.

A deliberate climb from heritage to One-Health genomics.



From digital genealogy to a multi-line genomics platform, each stage compounding capability, data and trust..


Five revenue lines, one reinforcing data ecosystem.





Growth Path & Milestones

A staged path from pilots to pharmaceutical value.



Transaction Route to Market

RSE Investment Clinic Application

RSE Investment Clinic → readiness assessment → advisory
→ validation → profiling → investor access.



RSE Investment Clinic Application

iGiTREE applied to the RSE Investment Clinic in FY 2025 and was screened against the programme's selection criteria.

- **Investor Readiness Diagnostic:**
Experts assessed iGiTREE's strengths and gaps across governance, financial management, legal compliance and business strategy.
- **Capacity Building & Advisory:**
iGiTREE received tailored recommendations and advisory support to address identified gaps and strengthen its investment readiness.
- **Due Diligence & Validation:**
Following implementation of the recommendations, iGiTREE underwent further assessment to validate its readiness to engage investors.
- **Official Profiling:**
iGiTREE successfully advanced to the profiling stage, positioning the company for introduction to potential investors and the broader capital-market ecosystem.



Market Overview

How iGiTREE's integrated genomics platform creates value across key markets

Who we serve.

Market	Core Need	iGiTREE Solution
Families & Diaspora Community	Reconnection & heritage	DNA + AI + Family Trees
Schools & Educational Institutions	Heritage Preservation & learning	Digital Family Trees + Education
Livestock Cooperatives, Breeders & Farmers	Productivity & traceability	Animal Genomics + Certification
Health & Research	Precision & population health	Human Genomics
Government & NGOs	Surveillance & One Health	Genomic Surveillance

Detailed applications across human, animal, health and environmental genomics

- **1. Families, Diaspora & Communities Seeking Reconnection**
iGITREE serves families, individuals, diaspora communities and survivor groups seeking DNA-based lineage reconstruction, heritage verification and family reunification. The platform combines DNA matching, AI-assisted kinship analysis and digital family-tree reconstruction to address family reconnection and cultural heritage needs, including communities affected by conflict, migration and historical displacement.
- **2. Schools & Educational Institutions**
iGITREE targets primary, secondary and international schools seeking to integrate digital heritage, cultural identity and technology-enabled learning. Its offering combines digital family trees, heritage-learning content and parent-student engagement tools, supported by teacher resources and curriculum-aligned activities.
- **3. Health & Research Institutions**
iGITREE targets hospitals, clinics, diagnostic centres and medical research institutions exploring the use of genomics for precision medicine, disease-risk assessment, pharmacogenomics and population health research. The human-genomics offering is designed to support genomic analysis, interpretation and clinician/researcher-ready reporting.

- **4. Livestock Cooperatives, Breeders & Farmers**
iGITREE targets farmers, commercial breeders, livestock cooperatives, veterinary institutions and agricultural programmes seeking genomic tools for productivity, resilience, breeding and traceability.

Its animal genomics offering combines DNA profiling, genetic trait analysis, breeding recommendations and lineage records, with particular relevance to high-value and indigenous breeds such as Inyambo cattle.

- **5. Governments, NGOs & Public-Health Agencies**
iGITREE targets government institutions, humanitarian organisations, environmental agencies and public-health programmes requiring genomic surveillance and One Health intelligence.

Applications include pathogen and antimicrobial-resistance surveillance, biodiversity monitoring and genomic data systems supporting evidence-based public-health and environmental decision-making.



Financial Overview

Projected Growth, Profitability & Investment Requirement



Investment Requirement

~ USD 2.5 M

Estimated Investment
Size



Projected Turnover

~ USD 4.7 M

Years 10



Projected Operating Profit

~ USD 3.8 M

Year 10



Projected Net Income


~ USD 2.4 M

Year 10


Projected Margin Profile (Average)




Average Gross Profit Margin



Average Operating Profit Margin




Average Net Profit Margin



Africa represents a growing regional opportunity within a USD 107.56B global

Global Genomics Market



Rest of World - USD 106.02B (98.57%)



Africa - USD 1.54B (1.43%)

A rapidly expanding market driven by increasing investments in healthcare, agriculture, research and innovation.

Source: The Business Research Company, Genomics Global Market Report 2026

2	Profit & Loss Statement								
3		2026	2027	2028	2029	2030	2031	2032	2033
4	Revenue	350,000,000	1,810,500,000	2,168,500,000	2,691,340,000	3,113,850,000	3,566,600,000	4,235,900,000	4,771,300,000
5	COS-Cost of Services								
6	Gross Profit	350,000,000	1,810,500,000	2,168,500,000	2,691,340,000	3,113,850,000	3,566,600,000	4,235,900,000	4,771,300,000
7	% of revenue	100%	100%	100%	100%	100%	100%	100%	100%
8	Operating expenses								
9	Office Supplies	(74,880,000)	(116,811,600)	(120,788,412)	(127,043,601)	(131,596,653)	(139,468,419)	(144,681,208)	(150,258,891)
10	Personnel Expenses	(192,080,000)	(360,870,000)	(372,176,100)	(372,176,100)	(383,854,983)	(395,920,187)	(395,920,187)	(408,385,812)
11	IT supplies	(1,765,800)	(1,889,406)	(2,021,665)	(2,163,182)	(2,314,605)	(2,476,627)	(2,649,990)	(2,835,489)
12	Other Supplies	-	(224,059,460)	(239,743,622)	(256,525,676)	(274,482,474)	(293,696,247)	(314,254,987)	(336,252,837)
13		(268,725,800)	(703,630,466)	(734,729,799)	(757,908,559)	(792,248,715)	(831,561,480)	(857,506,372)	(897,733,029)
14	Operating Income (EBITDA)	81,274,200	1,106,869,534	1,433,770,201	1,933,431,441	2,321,601,285	2,735,038,520	3,378,393,628	3,873,566,971
15	% of revenue	23%	61%	66%	72%	75%	77%	80%	81%
16	Depreciation and Amortization	(21,600,000)	(446,631,571)	(446,631,571)	(446,631,571)	(440,031,567)	(15,000,000)	(15,000,000)	(15,000,000)
17	Earnings Before Interest & Taxes (EBIT)	59,674,200	660,237,963	987,138,630	1,486,799,870	1,881,569,718	2,720,038,520	3,363,393,628	3,858,566,971
18	Interest Expense	-	(400,000,000)	(400,000,000)	(400,000,000)	(400,000,000)	(400,000,000)	(400,000,000)	(400,000,000)
19	Earnings Before Taxes (EBT)	59,674,200	260,237,963	587,138,630	1,086,799,870	1,481,569,718	2,320,038,520	2,963,393,628	3,458,566,971
20	Provision for taxation	(16,708,776)	(72,866,630)	(164,398,816)	(304,303,964)	(414,839,521)	(649,610,786)	(829,750,216)	(968,398,752)
21	Net Profit	42,965,424	187,371,333	422,739,814	782,495,906	1,066,730,197	1,670,427,734	2,133,643,412	2,490,168,219
22	% of revenue	12%	10%	19%	29%	34%	47%	50%	52%

Ten reasons iGiTREE is a compelling investment.

- 1 Massive, growing market:**
USD 107.56 Bn global genomics by 2030, ~16% CAGR.
- 2 Right place, right time**
Rwanda's National Genomic Strategy supports a favourable policy environment.
- 3 Unique integrated model**
Only One-Health genomics platform with local depth.
- 4 Five diversified revenue lines**
Human, animal, environment, education and data.
- 5 Proven early traction**
Reunification services delivered; school programme launched with Green Hills.
- 6 Powerful unit economics**
Projected operating leverage supports EBITDA margin of up to 81%.
- 7 Recurring + compounding IP**
Recurring sample-based revenue with potential for future licensable IP.
- 8 Defensible Competitive advantages**
Data, integration, cultural relevance and governance.
- 9 Relationships and collaborations across**
public-sector, research and technology institutions.
- 10 Attractive projected financial trajectory.**
~45% projected CAGR and RWF 8.8Bn cumulative projected profit, with declining leverage.



PARTNER WITH US TO BUILD
AFRICA'S GENOMIC FUTURE.

An integrated One Health genomics platform
delivering commercial value alongside social,
cultural and public-health impact across
Rwanda and Africa.

TURNING LINEAGE
INTO
LIFE-SAVING SCIENCE.